Studies of a Novel CCK-B/Gastrin Receptor Splice Variant
Studies of a Novel CCK-B/Gastrin Receptor Splice Variant
批准号:
6517796
负责人:
MARK R HELLMICH
金额:
$25.43万
依托单位国家:
美国
项目类别:
财政年份:
2001
资助国家:
美国
项目状态:
已结题
起止时间:
2001-07-01 至 2006-05-31
关键词:
biomarker calcium flux carcinogenesis cell growth regulation cholecystokinin colorectal neoplasms gastrins genetically modified animals hormone receptor human tissue laboratory mouse neoplastic growth neuropeptide receptor protein isoforms protein structure function protooncogene receptor expression receptor sensitivity tissue /cell culture transfection
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (Applicant's Abstract): Colorectal cancer is the third leading
cause of cancer death in the United States, Colon carcinogenesis is a complex,
multi-step process involving progressive changes in signaling pathways
regulating intestinal epithelial cell proliferation, differentiation and
programmed death. The peptide hormone, gastrin 1-17 (G-17), and its
non-amidated precursor, glycine-extended gastrin (G-GIy), exert potent trophic
effects on colon cancer cells. The long-term goal is to understand the role of
these peptide hormones in the regulation of epithelial cell biology and colon
carcinogenesis. Although the growth-promoting effect of these peptides on colon
cancers has been extensively documented, the identity of the receptors and
intracellular signaling pathways involved remain controversial. The
investigators have identified and isolated the cDNA for a novel splice variant
of the human cholecystokinin-B/gastrin receptor (CCK-BR), a member of the G
protein-coupled receptor (GPCR) superfamily. The splice variant (designated
CCK-BRi4sv for intron 4 containing splice variant) encodes a receptor protein
containing 69 additional amino acid residues in its putative third
intracellular loop domain. CCK-BRi4sv is expressed in adenomatous polyps and
colorectal cancers, but not in nonmalignant colonic mucosa adjacent to the
cancer. Mouse Balb3T3 cells expressing the splice variant exhibited
spontaneous, ligand-independent, oscillatory, increases in [Ca2+]i whereas, the
same cells expressing wild-type CCK-BR (CCK-BRwt) did not. Similarly, primary
cultures of human cells isolated from freshly resected colorectal cancers
exhibited, ligand-independent, oscillatory increases in [Ca2+]. For both
Balb3T3 and primary tumor cells, application of G-17 (10 and 200 nM,
respectively) caused an increase in [Ca2+]i. Selective CCK-BR antagonists
blocked the G- 17-stimulated Ca2+ responses, but not the spontaneous [Ca2+]i
oscillations. In addition to spontaneous intracellular signaling, BaIb3T3 cells
expressing CCK-BRi4sv exhibited an increased rate of cell proliferation
(approximately 2.5-fold), in the absence of G-17, compared to cells expressing
wild-type CCK-BR (CCK-BRwt). Based on these findings, the PI hypothesizes that
CCK-BRi4sv may regulate colorectal cancer cell growth through both a
gastrin-independent and -dependent mechanism and thus play a significant role
in colorectal carcinogenesis. Furthermore, the PI hypothesizes that the
function of CCK-BRi4sv in colorectal cancer biology is a direct consequence of
the structural changes in the third intracellular loop domain, caused by intron
retention, and the impact of those changes on intracellular signal
transduction. To examine these hypotheses they plan experiments with the
following specific aims: 1) to determine the spatial and temporal expression of
the CCK-BR splice variant in adenomatous polyps and colon cancers; 2) to
determine the effects of intron retention on receptor-mediated intracellular
signal transduction and receptor desensitization/internalization; and 3) to
determine the effects of ectopic expression of the CCK-BR splice variant on
colonic epithelial cell homeostasis and susceptibility to carcinogen-induced
colon cancer using a transgenic mouse model. These studies will provide
important and new information regarding the role of the novel receptor splice
variant and G-17 and G-Gly in epithelial cell biology and colon carcinogenesis.
Furthermore, these studies may, in the future, provide the basis for the
development of innovative therapeutic strategies for the treatment of peptide
hormone-sensitive cancers.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
UTMB Clinical and Translational Science Award
-
批准号:9270638
-
项目类别:
-
资助金额:$26.18万
-
财政年份:2015
-
负责人:MARK R HELLMICH
-
依托单位:
NRSA Training Core
-
批准号:10101759
-
项目类别:
-
资助金额:$36.4万
-
财政年份:2015
-
负责人:MARK R HELLMICH
-
依托单位:
UTMB Clinical and Translational Science Award
-
批准号:9128785
-
项目类别:
-
资助金额:$33.5万
-
财政年份:2015
-
负责人:MARK R HELLMICH
-
依托单位:
UTMB Clinical and Translational Science Award
-
批准号:9085702
-
项目类别:
-
资助金额:$32.66万
-
财政年份:2015
-
负责人:MARK R HELLMICH
-
依托单位:
Role of Hydrogen Sulfide in Colorectal Tumors
-
批准号:9079450
-
项目类别:
-
资助金额:$31.26万
-
财政年份:2014
-
负责人:MARK R HELLMICH
-
依托单位:
Role of Hydrogen Sulfide in Colorectal Tumors
-
批准号:8708260
-
项目类别:
-
资助金额:$31.24万
-
财政年份:2014
-
负责人:MARK R HELLMICH
-
依托单位:
CORE--PEPTIDE RECEPTOR CORE LABORATORY
-
批准号:6907132
-
项目类别:
-
资助金额:$14.33万
-
财政年份:2005
-
负责人:MARK R HELLMICH
-
依托单位:
Studies of a Novel CCK-B/Gastrin Receptor Splice Variant
-
批准号:6896603
-
项目类别:
-
资助金额:$27.79万
-
财政年份:2001
-
负责人:MARK R HELLMICH
-
依托单位:
Studies of a Novel CCK-B/Gastrin Receptor Splice Variant
-
批准号:6332317
-
项目类别:
-
资助金额:$25.95万
-
财政年份:2001
-
负责人:MARK R HELLMICH
-
依托单位:
Studies of a Novel CCK-B/Gastrin Receptor Splice Variant
-
批准号:6752509
-
项目类别:
-
资助金额:$26.98万
-
财政年份:2001
-
负责人:MARK R HELLMICH
-
依托单位:
Studies of a Novel CCK-B/Gastrin Receptor Splice Variant
-
批准号:6635297
-
项目类别:
-
资助金额:$26.82万
-
财政年份:2001
-
负责人:MARK R HELLMICH
-
依托单位:
Surgical Studies of GI Peptides - Mechanisms of Action
-
批准号:7271237
-
项目类别:
-
资助金额:$46.7万
-
财政年份:1994
-
负责人:MARK R HELLMICH
-
依托单位:
Surgical Studies of GI Peptides - Mechanisms of Action
-
批准号:7834628
-
项目类别:
-
资助金额:$46.7万
-
财政年份:1994
-
负责人:MARK R HELLMICH
-
依托单位:
Surgical Research Training in Gastrointestinal Diseases
-
批准号:9320839
-
项目类别:
-
资助金额:$20.92万
-
财政年份:1992
-
负责人:MARK R HELLMICH
-
依托单位:
Surgical Research Training in Gastroiontestinal Disease
-
批准号:7901057
-
项目类别:
-
资助金额:$10.73万
-
财政年份:1992
-
负责人:MARK R HELLMICH
-
依托单位:
Surgical Research Training in Gastroiontestinal Disease
-
批准号:7630399
-
项目类别:
-
资助金额:$12.8万
-
财政年份:1992
-
负责人:MARK R HELLMICH
-
依托单位:
Surgical Research Training in Gastrointestinal Diseases
-
批准号:8475293
-
项目类别:
-
资助金额:$18.32万
-
财政年份:1992
-
负责人:MARK R HELLMICH
-
依托单位:
Surgical Research Training in Gastroiontestinal Disease
-
批准号:8302440
-
项目类别:
-
资助金额:$2.37万
-
财政年份:1992
-
负责人:MARK R HELLMICH
-
依托单位:
Surgical Research Training in Gastrointestinal Diseases
-
批准号:8691784
-
项目类别:
-
资助金额:$19.27万
-
财政年份:1992
-
负责人:MARK R HELLMICH
-
依托单位:
Surgical Research Training in Gastrointestinal Diseases
-
批准号:8879283
-
项目类别:
-
资助金额:$6.42万
-
财政年份:1992
-
负责人:MARK R HELLMICH
-
依托单位:
海外基金